| Jul 29 |
Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity
|
| Jul 24 |
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
|
| Jul 18 |
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
|
| Jul 7 |
2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect
|
| Jul 5 |
Pendopharm and Ascendis to distribute hypoparathyroidism treatment
|
| Jul 5 |
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
|
| Jul 4 |
Pendopharm signs distribution agreement with Ascendis Pharma for TransCon PTH in Canada
|
| Jul 4 |
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada
|
| Jun 24 |
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
|
| Jun 21 |
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
|
